Completed PHASE1 INTERVENTIONAL 2-arm NCT01744652

Dasatinib and Crizotinib in Advanced Cancer

A Phase I Trial of Dasatinib in Combination With Crizotinib in Patients With Advanced Malignancies

Sponsor: M.D. Anderson Cancer Center

Updated 10 times since 2017 Last updated: Jun 6, 2023 Started: Mar 31, 2013 Primary completion: Mar 31, 2019 Completion: Mar 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01744652, this PHASE1 trial focuses on Advanced Cancers and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 10 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jul 2023 — Jul 2024 [monthly]

Completed PHASE1
Jul 2022 — Jul 2023 [monthly]

Completed PHASE1
Jan 2021 — Jul 2022 [monthly]

Completed PHASE1

▶ Show 5 earlier versions

Aug 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jun 2018 — Aug 2019 [monthly]

Active Not Recruiting PHASE1
Oct 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1
Feb 2017 — Oct 2017 [monthly]

Active Not Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Mar 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
Pfizer

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States